Author Correction: Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Author Correction: Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction ; volume:56 ; number:1 ; day:15 ; month:1 ; year:2024 ; pages:250 ; date:1.2024
Experimental & molecular medicine ; 56, Heft 1 (15.1.2024), 250, 1.2024
- Urheber
-
Kim, Inho
Cho, Hyun-Jai
Lim, Soo
Seok, Seung Hyeok
Lee, Hae-Young
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s12276-023-01154-2
- URN
-
urn:nbn:de:101:1-2024041509593212629092
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kim, Inho
- Cho, Hyun-Jai
- Lim, Soo
- Seok, Seung Hyeok
- Lee, Hae-Young
- SpringerLink (Online service)
Ähnliche Objekte (12)
Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction
Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction
Empagliflozin improves cardiac function in heart failure with reduced ejection fraction independent of loading conditions
Dynamic trajectories of left ventricular ejection fraction in heart failure with improved ejection fraction
Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
Right ventricular ejection fraction
Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
Animal models of heart failure with preserved ejection fraction
Extraction of Ejection Fraction from Echocardiography Notes for Constructing a Cohort of Patients having Heart Failure with reduced Ejection Fraction (HFrEF)
Evaluation of mouse models of heart failure with preserved ejection fraction
Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction
Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction
Empagliflozin improves cardiac function in heart failure with reduced ejection fraction independent of loading conditions
Dynamic trajectories of left ventricular ejection fraction in heart failure with improved ejection fraction
Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
Right ventricular ejection fraction
Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
Animal models of heart failure with preserved ejection fraction
Extraction of Ejection Fraction from Echocardiography Notes for Constructing a Cohort of Patients having Heart Failure with reduced Ejection Fraction (HFrEF)
Evaluation of mouse models of heart failure with preserved ejection fraction
Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction
Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction
Empagliflozin improves cardiac function in heart failure with reduced ejection fraction independent of loading conditions
Dynamic trajectories of left ventricular ejection fraction in heart failure with improved ejection fraction
Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
Right ventricular ejection fraction
Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
Animal models of heart failure with preserved ejection fraction
Extraction of Ejection Fraction from Echocardiography Notes for Constructing a Cohort of Patients having Heart Failure with reduced Ejection Fraction (HFrEF)